✦ LIBER ✦

Population Pharmacokinetics of Rituximab (Anti-CD20 Monoclonal Antibody) in Rheumatoid Arthritis Patients During a Phase II Clinical Trial

✍ Scribed by Ng, Chee M.; Bruno, Rene; Combs, Dan; Davies, Brian

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Rituximab (anti-CD20 monoclonal antibody

✍ Gerald Jäeger; Peter Neumeister; Ruth Brezinschek; Gerald Höfler; Franz Quehenbe 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 121 KB

Ocrelizumab, a humanized anti-CD20 monoc

✍ Mark C. Genovese; Jeffrey L. Kaine; Mitchell B. Lowenstein; José Del Giudice; An 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 623 KB

Safety, tolerability, pharmacokinetics a

✍ Ernest H Choy,Marina Bendit,Dana McAleer,Feng Liu… 📂 Article 📅 2013 🏛 BioMed Central 🌐 English ⚖ 362 KB

A Phase I trial of B-cell depletion with

✍ R Eisenberg, D Albert, J Stansberry, D Tsai, S Kolasinski, S Khan 📂 Article 📅 2003 🏛 BioMed Central 🌐 English ⚖ 554 KB

Clinical trials of a mouse-human chimeri

✍ Kensei Tobinai 📂 Article 📅 2001 🏛 Springer 🌐 English ⚖ 130 KB

Clinical Pharmacology of an Anti-CD4 Mon

✍ Heleen Scheerens; Yanan Zheng; John Davis; Zheng Su; Rong Deng; Sally Fischer; C 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 44 KB